StockData
Oruka Therapeutics, Inc. logo

Oruka Therapeutics, Inc. (ORKA) stock

ORKANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$96.32−2.92 (-2.94%)

Close on Nov 17, 2026Market cap $6.38BP/E –Yield –

Oruka Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Oruka Therapeutics's total assets was $1.14B at Jun 30, 2026. For fiscal 2025 it was $488.62M, up 23.4% from the year before. Over ten years it grew 28.6% a year on average. The highest annual figure on record is $488.62M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$488.62M+23.4%
FY2024Dec 31, 2024$396.02M+946.0%
FY2023Dec 31, 2023$37.86M-12.1%
FY2022Dec 31, 2022$43.09M-21.6%
FY2021Dec 31, 2021$54.92M+8.9%
FY2020Dec 31, 2020$50.43M+490.8%
FY2019Dec 31, 2019$8.54M+25.1%
FY2018Dec 31, 2018$6.83M-44.8%
FY2017Dec 31, 2017$12.37M-49.8%
FY2016Dec 31, 2016$24.63M-37.8%
FY2015Dec 31, 2015$39.57M+145.3%
FY2014Dec 31, 2014$16.13M-5.6%
FY2013Dec 31, 2013$17.08M+431.9%
FY2012Dec 31, 2012$3.21M-50.6%
FY2011Dec 31, 2011$6.50M-20.3%
FY2010Dec 31, 2010$8.16M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.14B+218.8%
Q1 FY2026Mar 31, 2026$504.48M+33.8%
Q4 FY2025Dec 31, 2025$488.62M+23.4%
Q3 FY2025Sep 30, 2025$509.25M+23.0%
Q2 FY2025Jun 30, 2025$357.42M+956.1%
Q1 FY2025Mar 31, 2025$377.11M+927.4%
Q4 FY2024Dec 31, 2024$396.02M+946.0%
Q3 FY2024Sep 30, 2024$414.09M+956.8%
Q2 FY2024Jun 30, 2024$33.84M-17.6%
Q1 FY2024Mar 31, 2024$36.71M-12.7%
Q4 FY2023Dec 31, 2023$37.86M-12.1%
Q3 FY2023Sep 30, 2023$39.18M-12.9%
Q2 FY2023Jun 30, 2023$41.08M-14.6%
Q1 FY2023Mar 31, 2023$42.06M-17.6%
Q4 FY2022Dec 31, 2022$43.09M-21.6%
Q3 FY2022Sep 30, 2022$44.97M-25.3%
Q2 FY2022Jun 30, 2022$48.10M-26.4%
Q1 FY2022Mar 31, 2022$51.01M-26.3%
Q4 FY2021Dec 31, 2021$54.92M+8.9%
Q3 FY2021Sep 30, 2021$60.19M+15.8%
Q2 FY2021Jun 30, 2021$65.34M+775.7%
Q1 FY2021Mar 31, 2021$69.18M+710.5%
Q4 FY2020Dec 31, 2020$50.43M+406.9%
Q3 FY2020Sep 30, 2020$51.98M+400.4%
Q1 FY2020Mar 31, 2020$7.46M-13.3%
Q4 FY2019Dec 31, 2019$8.54M+25.1%
Q3 FY2019Sep 30, 2019$9.95M+17.8%
Q2 FY2019Jun 30, 2019$10.39M+3.2%
Q1 FY2019Mar 31, 2019$8.61M-32.7%
Q4 FY2018Dec 31, 2018$6.83M-44.8%
Q3 FY2018Sep 30, 2018$8.45M-50.1%
Q2 FY2018Jun 30, 2018$10.07M-41.8%
Q1 FY2018Mar 31, 2018$12.79M-37.9%
Q4 FY2017Dec 31, 2017$12.37M-49.8%
Q3 FY2017Sep 30, 2017$16.92M-41.0%
Q2 FY2017Jun 30, 2017$17.30M-47.0%
Q1 FY2017Mar 31, 2017$20.59M–
Q4 FY2016Dec 31, 2016$24.63M–
Q3 FY2016Sep 30, 2016$28.68M–
Q2 FY2016Jun 30, 2016$32.64M–

More Oruka Therapeutics figures

See a number that looks wrong?